Perspective Therapeutics, Inc. (CATX)
2.34
+0.10
(+4.46%)
USD |
NYAM |
Oct 15, 16:00
2.35
+0.01
(+0.43%)
After-Hours: 20:00
Perspective Therapeutics Cash from Operations (TTM) : -93.07M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -93.07M |
| March 31, 2026 | -92.37M |
| December 31, 2025 | -82.48M |
| September 30, 2025 | -84.43M |
| June 30, 2025 | -64.78M |
| March 31, 2025 | -53.72M |
| December 31, 2024 | -18.29M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | -30.80M |
| June 30, 2023 | -22.11M |
| March 31, 2023 | -15.35M |
| June 30, 2022 | -7.71M |
| March 31, 2022 | -5.937M |
| December 31, 2021 | -5.136M |
| September 30, 2021 | -4.583M |
| June 30, 2021 | -2.837M |
| March 31, 2021 | -2.567M |
| December 31, 2020 | -2.808M |
| September 30, 2020 | -3.326M |
| June 30, 2020 | -3.641M |
| March 31, 2020 | -3.778M |
| December 31, 2019 | -4.254M |
| Date | Value |
|---|---|
| September 30, 2019 | -4.09M |
| June 30, 2019 | -5.049M |
| March 31, 2019 | -5.512M |
| December 31, 2018 | -5.254M |
| September 30, 2018 | -5.663M |
| June 30, 2018 | -5.712M |
| March 31, 2018 | -5.477M |
| December 31, 2017 | -5.882M |
| September 30, 2017 | -6.02M |
| June 30, 2017 | -5.712M |
| March 31, 2017 | -5.707M |
| December 31, 2016 | -4.978M |
| September 30, 2016 | -4.127M |
| June 30, 2016 | -3.884M |
| March 31, 2016 | -3.305M |
| December 31, 2015 | -3.684M |
| September 30, 2015 | -3.488M |
| June 30, 2015 | -3.522M |
| March 31, 2015 | -3.882M |
| December 31, 2014 | -3.248M |
| September 30, 2014 | -3.479M |
| June 30, 2014 | -3.228M |
| March 31, 2014 | -3.026M |
| December 31, 2013 | -3.281M |
| September 30, 2013 | -3.010M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Anika Therapeutics, Inc. | 5.977M |
| MiMedx Group, Inc. | 46.13M |
| ABVC BioPharma, Inc. | -2.691M |
| Enovis Corp. | 270.10M |
| Edwards Lifesciences Corp. | 1.720B |